Match!
Matthew Meyerson
Broad Institute
641Publications
154H-index
127kCitations
Publications 641
Newest
#1Minsuh KimH-Index: 1
#2Hyemin MunH-Index: 1
Last.Se Jin Jang (UOU: University of Ulsan)H-Index: 37
view all 16 authors...
Lung cancer shows substantial genetic and phenotypic heterogeneity across individuals, driving a need for personalised medicine. Here, we report lung cancer organoids and normal bronchial organoids established from patient tissues comprising five histological subtypes of lung cancer and non-neoplastic bronchial mucosa as in vitro models representing individual patient. The lung cancer organoids recapitulate the tissue architecture of the primary lung tumours and maintain the genomic alterations ...
#1Timothy A. Lewis (Broad Institute)H-Index: 20
Last.Matthew MeyersonH-Index: 154
view all 0 authors...
6-(4-(Diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one, or DNMDP, potently and selectively inhibits phosphodiesterases 3A and 3B (PDE3A and PDE3B) and kills cancer cells by inducing PDE3A/B interactions with SFLN12. The structure-activity relationship (SAR) of DNMDP analogs was evaluated using a phenotypic viability assay, resulting in several compounds with suitable pharmacokinetic properties for in vivo analysis. One of these compounds, BRD9500, was active in an SK-MEL-3 xe...
#1Steven M. Corsello (Harvard University)H-Index: 7
#2Rohith T. Nagari (Broad Institute)
Last.Todd R. Golub (Broad Institute)H-Index: 131
view all 0 authors...
Anti-cancer uses of non-oncology drugs have been found on occasion, but such discoveries have been serendipitous and rare. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs tested across 578 human cancer cell lines. To accomplish this, we used PRISM, which involves drug treatment of molecularly barcoded cell lines in pools. Relative barcode abundance following treatment thus reflects viability of each cell line. We found that an unexpectedly large num...
#1Tikvah K. Hayes (Broad Institute)
#2Flora Luo (Broad Institute)H-Index: 5
Last.Cory M. Johannessen (Broad Institute)H-Index: 9
view all 12 authors...
Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. To prospectively map the landscape of resistance to this investigational regimen, we utilized a series of gain- and loss-of-function forward genetic screens to identify modulators of resistance to clinical inhibitors of MEK1/2 and CDK4/6 alone and in combination. First, we identified NRAS-mutant melanoma cell lines that were dependent on NRAS for proliferation and sensitive to ME...
#1Diana Cai (Broad Institute)H-Index: 4
#2Peter S. Choi (Broad Institute)H-Index: 12
Last.Matthew Meyerson (Broad Institute)H-Index: 154
view all 4 authors...
Lung adenocarcinomas are characterized by mutations in the receptor tyrosine kinase (RTK)/Ras/Raf pathway, with up to 75% of cases containing mutations in known driver genes. However, the driver alterations in the remaining cases are yet to be determined. Recent exome sequencing analysis has identified SOS1 , encoding a guanine nucleotide exchange factor, as significantly mutated in lung adenocarcinomas lacking canonical oncogenic RTK/Ras/Raf pathway mutations. Here, we demonstrate that ectopic ...
#1Tao Zou (Broad Institute)H-Index: 1
#2Matthew MeyersonH-Index: 154
Circulating tumor DNA (ctDNA) holds great promise as a noninvasive diagnostic tool to guide treatment for patients with lung cancer. Two studies by Phallen and colleagues and Anagnostou and colleagues correlated sensitive measures of ctDNA with clinical responses to tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors, respectively, in patients with non–small cell lung cancer (NSCLC). Together, these studies further highlight the potential clinical utility of serial ctDNA monitoring...
#1Barbara Tabak (Broad Institute)H-Index: 17
#2Gordon Saksena (Broad Institute)H-Index: 45
Last.Gad Getz (Broad Institute)H-Index: 129
view all 14 authors...
Abstract Motivation Somatic copy-number alterations (SCNAs) play an important role in cancer development. Systematic noise in sequencing and array data present a significant challenge to the inference of SCNAs for cancer genome analyses. As part of The Cancer Genome Atlas (TCGA), the Broad Institute Genome Characterization Center developed the Tangent copy-number inference pipeline to generate copy-number profiles using single-nucleotide polymorphism (SNP) array and whole-exome sequencing (WES) ...
12345678910